Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic changing mass behind the left atrium.

BMJ case reports·2025
Same author

Comparative analysis of cryoballoon versus radiofrequency catheter ablation in atrial fibrillation patients with impaired left ventricular ejection fraction.

International journal of cardiology. Heart & vasculature·2025
Same author

Macrophages enhance sodium channel expression in cardiomyocytes.

Basic research in cardiology·2024
Same author

Cardiomyocyte-specific RXFP1 overexpression protects against pressure overload-induced cardiac dysfunction independently of relaxin.

Biochemical pharmacology·2024
Same author

[Digitalization and clinical decision tools].

Herz·2024
Same author

Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.

European heart journal. Cardiovascular pharmacotherapy·2023
Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Antiplatelet therapy - ticagrelor.

E Giannitsis1, H A Katus

  • 1Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Germany. evangelos_giannitsis@med.uni-heidelberg.de

Hamostaseologie
|June 29, 2012
PubMed
Summary
This summary is machine-generated.

Ticagrelor provides faster, more effective platelet inhibition than clopidogrel for acute coronary syndrome (ACS) patients. The PLATO trial showed ticagrelor reduced cardiovascular events without increasing major bleeding, establishing a new standard in dual antiplatelet therapy.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Experiment Videos

Last Updated: May 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Ticagrelor is a novel P2Y(12) receptor inhibitor, distinct from thienopyridines like clopidogrel.
  • Unlike prodrugs, ticagrelor does not require hepatic biotransformation for its antiplatelet effect.
  • This leads to more rapid, potent, and consistent platelet inhibition.

Purpose of the Study:

  • To validate the efficacy and safety of ticagrelor compared to clopidogrel in patients with acute coronary syndrome (ACS).
  • To assess ticagrelor's impact on major adverse cardiovascular events and bleeding risk.

Main Methods:

  • The Phase III PLATO trial randomized over 18,000 ACS patients to ticagrelor or clopidogrel.
  • Patients received treatment within 24 hours of symptom onset, regardless of planned invasive or conservative management.
  • Endpoints included cardiovascular death, non-fatal myocardial infarction (MI), stroke, and major bleeding.

Main Results:

  • Ticagrelor significantly reduced the primary endpoint (cardiovascular death, non-fatal MI, or stroke) compared to clopidogrel.
  • This benefit was observed without an increase in PLATO-defined major bleeding events.
  • Consistent efficacy was noted across various subgroups, including STEMI, planned invasive treatment, and patients with diabetes or renal failure.

Conclusions:

  • Ticagrelor represents a paradigm shift in dual antiplatelet therapy for ACS.
  • Current ESC guidelines recommend ticagrelor or prasugrel over clopidogrel when available and not contraindicated.